<p>Corton Capital Inc. 在第二季度购买了 Royalty Pharma PLC (NASDAQ:RPRX - 免费报告) 的新头寸，根据该公司最近向证券交易委员会提交的 13F 文件。该公司购买了 6,859 股生物制药公司的股票，价值约 247,000 美元。</p>
<p>获取 <strong>Royalty Pharma</strong> 警报：</p>
<ul>
<li>Royalty Pharma 如何在没有生物技术最大风险的情况下产生现金</li>
</ul>
<p>其他一些对冲基金也增加或减少了对该股票的持股。USA Financial Formulas 在第二季度购买了 Royalty Pharma 的新头寸，价值 32,000 美元。Summit Securities Group LLC 在第一季度购买了 Royalty Pharma 的新头寸，价值约 36,000 美元。WPG Advisers LLC 在第一季度购买了 Royalty Pharma 的新头寸，价值约 39,000 美元。Allworth Financial LP 在第一季度将其在 Royalty Pharma 的持股增加了 41.6%。Allworth Financial LP 目前拥有 1,539 股生物制药公司的股票，价值 49,000 美元，此前在上个季度又购买了 452 股。最后，MassMutual Private Wealth &amp; Trust FSB 在第二季度将其在 Royalty Pharma 的持股增加了 42.1%。MassMutual Private Wealth &amp; Trust FSB 目前拥有 1,358 股生物制药公司的股票，价值 49,000 美元，此前在此期间又购买了 402 股。54.35% 的股票目前由对冲基金和其他机构投资者持有。</p>
<h2>Royalty Pharma 股票下跌 0.6%</h2>
<p>RPRX 股票周二开盘价为 37.30 美元。该公司的债务与股本比率为 0.74，流动比率为 1.26，速动比率为 1.26。Royalty Pharma PLC 的一年低点为 24.05 美元，一年高点为 38.00 美元。该公司的 50 日移动平均价格为 36.22 美元，200 日移动平均价格为 35.27 美元。该公司的市值为 217.5 亿美元，市盈率为 21.56，PEG 比率为 2.06，贝塔值为 0.56。</p>
<ul>
<li>1 次试验，2 个特许经营：Zenas 股票因里程碑数据而上涨</li>
</ul>
<p>Royalty Pharma (NASDAQ:RPRX - 获取免费报告) 最近于 8 月 6 日星期三发布了季度财报。这家生物制药公司报告的每股收益 (EPS) 为 1.14 美元，超出分析师一致预期的 1.10 美元，超出 0.04 美元。该季度的收入为 5.7867 亿美元，而分析师预期为 7.5006 亿美元。Royalty Pharma 的股本回报率为 25.54%，净利润率为 44.23%。卖方分析师预计 Royalty Pharma PLC 本财年将发布 4.49 的每股收益。</p>
<h2>Royalty Pharma 分红公告</h2>
<p>该公司还最近宣布了一项季度分红，将于 12 月 10 日星期三支付。11 月 14 日星期五的登记投资者将获得每股 0.22 美元的分红。除息日为 11 月 14 日星期五。这代表着每年 0.88 美元的分红和 2.4% 的分红收益率。Royalty Pharma 的分红支付比率 (DPR) 目前为 50.87%。</p>
<h2>分析师升级和降级</h2>
<ul>
<li>4 只医疗保健股票大幅上涨——还有更多上涨空间</li>
</ul>
<p>几位股票分析师最近对该股票发表了看法。花旗集团在 7 月 22 日的研究报告中将 Royalty Pharma 的目标价从 40.00 美元上调至 42.00 美元，并给予该股票 &#34;买入&#34; 评级。华尔街 Zen 在周六的研究报告中将 Royalty Pharma 的评级从 &#34;持有&#34; 上调至 &#34;买入&#34;。高盛集团在 9 月 30 日的研究报告中开始覆盖 Royalty Pharma 的股票。他们对该股票设定了 &#34;买入&#34; 评级和 42.00 美元的目标价。Weiss Ratings 将 Royalty Pharma 的评级从 &#34;买入 (b-)&#34; 下调至 &#34;持有 (c+)&#34;，在 10 月 25 日的研究报告中。最后，摩根士丹利在 10 月 10 日的报告中将 Royalty Pharma 的目标价从 55.00 美元下调至 54.00 美元，并对该股票设定了 &#34;增持&#34; 评级。一位股票研究分析师对该股票给予了强烈买入评级，三位给予了买入评级，一位给予了持有评级。根据 MarketBeat 的数据，该公司目前的共识评级为 &#34;买入&#34;，共识目标价为 46.00 美元。</p>
<p><strong>阅读我们关于 RPRX 的最新报告</strong></p>
<h2>Royalty Pharma 公司简介</h2>
<p>(免费报告)</p>
<p>Royalty Pharma plc 在美国作为生物制药专利的买方和生物制药行业创新的资助者。它还参与各种生物制药疗法的专利的识别、评估和收购。此外，该公司与来自学术机构、研究医院和非营利组织、小型和中型生物技术公司以及制药公司的创新者合作。</p>
<h2>了解更多</h2>
<ul>
<li>五只我们更看好的股票，胜过 Royalty Pharma</li>
<li>什么是成长股及其投资</li>
<li>半导体超级周期：为什么 Onsemi 股票可能会因 AI 和电动车增长而翻倍</li>
<li>低市盈率成长股：解锁投资机会</li>
<li>感恩节最佳本地肉铺 [2025 调查]</li>
<li>Roth IRA 计算器：计算您的潜在回报</li>
<li>1.34 亿美元的内部交易：这可能对 KMI、ISRG 和 QS 意味着什么</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UlBSWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UlBSWA"/></p>
<p><em>此即时新闻警报由叙述科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Royalty Pharma 吗？</h2>
<p>在你考虑 Royalty Pharma 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Royalty Pharma 并不在名单上。</p>
<p>虽然 Royalty Pharma 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

RPRX

<p>Corton Capital Inc. 在其最近的 13F 文件中报告，在第二季度收购了 6,859 股 Royalty Pharma PLC（纳斯达克代码：RPRX），价值约为 247,000 美元。其他对冲基金也调整了在 Royalty Pharma 的持股。该股票开盘价为 37.30 美元，市值为 217.5 亿美元，市盈率为 21.56。Royalty Pharma 最近宣布每股季度股息为 0.22 美元，将于 12 月 10 日支付。分析师的评级意见不一，普遍评级为 “买入”，目标价格为 46.00 美元</p>

<p>Corton Capital Inc. bought a new position in Royalty Pharma PLC (NASDAQ:RPRX - Free Report) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities &amp; Exchange Commission. The firm bought 6,859 shares of the biopharmaceutical company's stock, valued at approximately $247,000.</p>
<div class="lb-trans"><p>Corton Capital Inc. 在第二季度购买了 Royalty Pharma PLC (NASDAQ:RPRX - 免费报告) 的新头寸，根据该公司最近向证券交易委员会提交的 13F 文件。该公司购买了 6,859 股生物制药公司的股票，价值约 247,000 美元。</p>
</div><p>Get <strong>Royalty Pharma</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Royalty Pharma</strong> 警报：</p>
</div><ul>
<li>How Royalty Pharma Prints Cash Without Biotech's Biggest Risks</li>
</ul>
<div class="lb-trans"><ul>
<li>Royalty Pharma 如何在没有生物技术最大风险的情况下产生现金</li>
</ul>
</div><p>A number of other hedge funds have also added to or reduced their stakes in the stock. USA Financial Formulas purchased a new position in shares of Royalty Pharma in the 2nd quarter worth $32,000. Summit Securities Group LLC bought a new position in Royalty Pharma in the first quarter valued at about $36,000. WPG Advisers LLC bought a new position in Royalty Pharma in the first quarter valued at about $39,000. Allworth Financial LP boosted its position in Royalty Pharma by 41.6% in the first quarter. Allworth Financial LP now owns 1,539 shares of the biopharmaceutical company's stock worth $49,000 after purchasing an additional 452 shares during the last quarter. Finally, MassMutual Private Wealth &amp; Trust FSB grew its stake in shares of Royalty Pharma by 42.1% during the 2nd quarter. MassMutual Private Wealth &amp; Trust FSB now owns 1,358 shares of the biopharmaceutical company's stock valued at $49,000 after purchasing an additional 402 shares during the period. 54.35% of the stock is currently owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>其他一些对冲基金也增加或减少了对该股票的持股。USA Financial Formulas 在第二季度购买了 Royalty Pharma 的新头寸，价值 32,000 美元。Summit Securities Group LLC 在第一季度购买了 Royalty Pharma 的新头寸，价值约 36,000 美元。WPG Advisers LLC 在第一季度购买了 Royalty Pharma 的新头寸，价值约 39,000 美元。Allworth Financial LP 在第一季度将其在 Royalty Pharma 的持股增加了 41.6%。Allworth Financial LP 目前拥有 1,539 股生物制药公司的股票，价值 49,000 美元，此前在上个季度又购买了 452 股。最后，MassMutual Private Wealth &amp; Trust FSB 在第二季度将其在 Royalty Pharma 的持股增加了 42.1%。MassMutual Private Wealth &amp; Trust FSB 目前拥有 1,358 股生物制药公司的股票，价值 49,000 美元，此前在此期间又购买了 402 股。54.35% 的股票目前由对冲基金和其他机构投资者持有。</p>
</div><h2>Royalty Pharma Stock Down 0.6%</h2>
<div class="lb-trans"><h2>Royalty Pharma 股票下跌 0.6%</h2>
</div><p>Shares of RPRX stock opened at $37.30 on Tuesday. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.26 and a quick ratio of 1.26. Royalty Pharma PLC has a one year low of $24.05 and a one year high of $38.00. The company's fifty day moving average price is $36.22 and its 200-day moving average price is $35.27. The company has a market capitalization of $21.75 billion, a price-to-earnings ratio of 21.56, a PEG ratio of 2.06 and a beta of 0.56.</p>
<div class="lb-trans"><p>RPRX 股票周二开盘价为 37.30 美元。该公司的债务与股本比率为 0.74，流动比率为 1.26，速动比率为 1.26。Royalty Pharma PLC 的一年低点为 24.05 美元，一年高点为 38.00 美元。该公司的 50 日移动平均价格为 36.22 美元，200 日移动平均价格为 35.27 美元。该公司的市值为 217.5 亿美元，市盈率为 21.56，PEG 比率为 2.06，贝塔值为 0.56。</p>
</div><ul>
<li>1 Trial, 2 Franchises: Zenas Stock Climbs on Landmark Data</li>
</ul>
<div class="lb-trans"><ul>
<li>1 次试验，2 个特许经营：Zenas 股票因里程碑数据而上涨</li>
</ul>
</div><p>Royalty Pharma (NASDAQ:RPRX - Get Free Report) last issued its quarterly earnings results on Wednesday, August 6th. The biopharmaceutical company reported $1.14 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.10 by $0.04. The business had revenue of $578.67 million during the quarter, compared to analyst estimates of $750.06 million. Royalty Pharma had a return on equity of 25.54% and a net margin of 44.23%. Sell-side analysts expect that Royalty Pharma PLC will post 4.49 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Royalty Pharma (NASDAQ:RPRX - 获取免费报告) 最近于 8 月 6 日星期三发布了季度财报。这家生物制药公司报告的每股收益 (EPS) 为 1.14 美元，超出分析师一致预期的 1.10 美元，超出 0.04 美元。该季度的收入为 5.7867 亿美元，而分析师预期为 7.5006 亿美元。Royalty Pharma 的股本回报率为 25.54%，净利润率为 44.23%。卖方分析师预计 Royalty Pharma PLC 本财年将发布 4.49 的每股收益。</p>
</div><h2>Royalty Pharma Dividend Announcement</h2>
<div class="lb-trans"><h2>Royalty Pharma 分红公告</h2>
</div><p>The firm also recently announced a quarterly dividend, which will be paid on Wednesday, December 10th. Investors of record on Friday, November 14th will be given a dividend of $0.22 per share. The ex-dividend date is Friday, November 14th. This represents a $0.88 annualized dividend and a dividend yield of 2.4%. Royalty Pharma's dividend payout ratio (DPR) is currently 50.87%.</p>
<div class="lb-trans"><p>该公司还最近宣布了一项季度分红，将于 12 月 10 日星期三支付。11 月 14 日星期五的登记投资者将获得每股 0.22 美元的分红。除息日为 11 月 14 日星期五。这代表着每年 0.88 美元的分红和 2.4% 的分红收益率。Royalty Pharma 的分红支付比率 (DPR) 目前为 50.87%。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师升级和降级</h2>
</div><ul>
<li>4 Healthcare Stocks With Massive Gains—and More to Come</li>
</ul>
<div class="lb-trans"><ul>
<li>4 只医疗保健股票大幅上涨——还有更多上涨空间</li>
</ul>
</div><p>Several equities analysts have recently weighed in on the stock. Citigroup increased their price objective on shares of Royalty Pharma from $40.00 to $42.00 and gave the stock a &#34;buy&#34; rating in a research note on Tuesday, July 22nd. Wall Street Zen upgraded shares of Royalty Pharma from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a research report on Saturday. The Goldman Sachs Group started coverage on shares of Royalty Pharma in a research note on Tuesday, September 30th. They set a &#34;buy&#34; rating and a $42.00 price target on the stock. Weiss Ratings lowered Royalty Pharma from a &#34;buy (b-)&#34; rating to a &#34;hold (c+)&#34; rating in a research note on Saturday, October 25th. Finally, Morgan Stanley decreased their target price on Royalty Pharma from $55.00 to $54.00 and set an &#34;overweight&#34; rating on the stock in a report on Friday, October 10th. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has given a Hold rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of &#34;Buy&#34; and a consensus target price of $46.00.</p>
<div class="lb-trans"><p>几位股票分析师最近对该股票发表了看法。花旗集团在 7 月 22 日的研究报告中将 Royalty Pharma 的目标价从 40.00 美元上调至 42.00 美元，并给予该股票 &#34;买入&#34; 评级。华尔街 Zen 在周六的研究报告中将 Royalty Pharma 的评级从 &#34;持有&#34; 上调至 &#34;买入&#34;。高盛集团在 9 月 30 日的研究报告中开始覆盖 Royalty Pharma 的股票。他们对该股票设定了 &#34;买入&#34; 评级和 42.00 美元的目标价。Weiss Ratings 将 Royalty Pharma 的评级从 &#34;买入 (b-)&#34; 下调至 &#34;持有 (c+)&#34;，在 10 月 25 日的研究报告中。最后，摩根士丹利在 10 月 10 日的报告中将 Royalty Pharma 的目标价从 55.00 美元下调至 54.00 美元，并对该股票设定了 &#34;增持&#34; 评级。一位股票研究分析师对该股票给予了强烈买入评级，三位给予了买入评级，一位给予了持有评级。根据 MarketBeat 的数据，该公司目前的共识评级为 &#34;买入&#34;，共识目标价为 46.00 美元。</p>
</div><p><strong>Read Our Latest Report on RPRX</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 RPRX 的最新报告</strong></p>
</div><h2>Royalty Pharma Company Profile</h2>
<div class="lb-trans"><h2>Royalty Pharma 公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>(免费报告)</p>
</div><p>Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.</p>
<div class="lb-trans"><p>Royalty Pharma plc 在美国作为生物制药专利的买方和生物制药行业创新的资助者。它还参与各种生物制药疗法的专利的识别、评估和收购。此外，该公司与来自学术机构、研究医院和非营利组织、小型和中型生物技术公司以及制药公司的创新者合作。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than Royalty Pharma</li>
<li>What Are Growth Stocks and Investing in Them</li>
<li>Semiconductor Supercycle: Why Onsemi Stock Could Double as AI and EV Growth Accelerate</li>
<li>Low PE Growth Stocks: Unlocking Investment Opportunities</li>
<li>The Best Local Butchers for Thanksgiving [2025 Survey]</li>
<li>Roth IRA Calculator: Calculate Your Potential Returns</li>
<li>$134M in Insider Moves: What It Might Mean for KMI, ISRG and QS</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Royalty Pharma</li>
<li>什么是成长股及其投资</li>
<li>半导体超级周期：为什么 Onsemi 股票可能会因 AI 和电动车增长而翻倍</li>
<li>低市盈率成长股：解锁投资机会</li>
<li>感恩节最佳本地肉铺 [2025 调查]</li>
<li>Roth IRA 计算器：计算您的潜在回报</li>
<li>1.34 亿美元的内部交易：这可能对 KMI、ISRG 和 QS 意味着什么</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UlBSWA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=RPRX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻警报由叙述科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Royalty Pharma Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Royalty Pharma 吗？</h2>
</div><p>Before you consider Royalty Pharma, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Royalty Pharma 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Royalty Pharma wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Royalty Pharma 并不在名单上。</p>
</div><p>While Royalty Pharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Royalty Pharma 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Corton Capital Inc. 收购了 Royalty Pharma PLC 的新股份